^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations

Published date:
03/13/2023
Excerpt:
In our multi-institution cohort (N=200), E746_A750del was associated with significantly prolonged progression free survival (PFS) with 1L osimertinib...
DOI:
https://doi.org/10.1158/1078-0432.CCR-22-3497